elu001
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 13, 2021 (NCT05001282)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Bile Duct Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Endometrioid · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Klatskin Tumor · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Liver Neoplasms · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Ovarian Diseases · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Diseases · Phase 1/Phase 2
Mechanism of action
- Folate receptor alphaBINDING AGENT
FOLR1 binding agent
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05622591 | Phase 1 | Mar 31, 2023 | Elucida Oncology |
| NCT05001282 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2021 | Elucida Oncology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elucida Oncology | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1